New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...
GSK (GSK) plc announced what it calls its “largest U.S. manufacturing investment to date.” The up to $800M investment will bring ...
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
In a 15-0 vote, ACIP recommended that MenB-4C be administered as a two-dose series at 0 and 6 months when given to healthy ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...
WHTM Harrisburg on MSN11h
GSK investing up to $800 million in Lancaster County facility expansionDeputies in Volusia County said they are seeing big results after taking action against school threats. Cameron Diaz is ...
Hundreds of millions of dollars and hundreds of new jobs are coming to Lancaster County. Vaccine manufacturer GSK announced Thursday it will invest $800 million to expand its Marietta location, ...
Last week, GlaxoSmithKline and Northwestern University filed separate lawsuits against Moderna, accusing its mRNA-based vaccines of ...
After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Global biopharma company GSK is investing up to $800 million in Pennsylvania and expanding its facility in Lancaster County.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback